Glenmark Pharmaceuticals Ltd: 1,284 Patents, 1 Big Makeover, and Zero Chill in R&D Spending
1. At a Glance
Glenmark is that pharma kid in the class who doesn’t just turn up with the homework — they bring it in four languages, with charts, patents, and a side hustle in biosimilars. With operations in 80+ countries, three therapy obsessions (dermatology, respiratory, oncology), and a global game plan that mixes generics with specialty launches, they’ve also been busy re-structuring their corporate wardrobe and selling off a chunk of Glenmark Life Sciences to Nirma for a cool ₹5,651 crore. Oh, and they’re burning through R&D cash faster than some startups burn VC funding — ₹916 crore in 9MFY24.
2. Introduction
If Indian pharma were a cricket match, Glenmark would be that middle-order batsman who’s always on the field — sometimes hitting sixes in Europe, sometimes playing safe in India, and occasionally getting caught out in the US generics market.
The company’s 14th largest status in India may not sound like front-page news until you notice it’s also the 2nd largest in respiratory and dermatology domestically, 15th in the US by generic prescriptions, and 5th in Europe among Indian peers. Translation: they’re not just playing the home game — they’re collecting air miles.
Its golden child right now is Ryaltris, a nasal spray that’s basically the poster child of their specialty portfolio, already sold in 31 countries and with approvals in another 18. Combine that with the Lirafit biosimilar launch at 70% lower therapy cost and you get the picture — Glenmark is leaning hard into differentiated products.
Also worth noting — they’ve been busy in the boardroom. Corporate restructuring has spun off innovation biologics (Ichnos Sciences), the consumer care business has been moved to a new subsidiary for ₹240 crore, and they’re gearing up to monetize innovation via alliances like Ichnos Glenmark Innovation.
3. Business Model (WTF Do They Even Do?)
Think of Glenmark as a three-course pharma meal:
Generics – The bread and butter (and sometimes stale toast) of revenue. Tablets, injectables, respiratory devices, ointments — you name it.
Specialty – Higher-margin products like Ryaltris, with global rollouts.
OTC – Consumer-facing products, soon to be managed via Glenmark Consumer Care Ltd.
The therapy obsessions are:
Respiratory – MDIs, DPIs, sprays, inhalers. Their pipeline includes generic pMDIs and nasal sprays, with multiple ANDAs filed.
Dermatology – Creams, gels, ointments that keep them in the top-tier in India.
Oncology – Still a long-term bet, with R&D money going into immunology and cancer drug development.
Manufacturing muscle? 14 facilities across 4 continents, 8 USFDA-approved, with 11 in India. And they’re not shy about closing or optimizing plants if margins demand it.
